Date: 2014-09-25
Type of information: Development agreement
Compound: up to five biosimilar products including Epirus\' Remicade® biosimilar BOW015
Company: Epirus Biopharmaceuticals (USA - MA) Livzon Mabpharm (China)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Type agreement: development production manufacturing commercialisation
Action mechanism:
Disease:
Details: * On September 25, 2014, Epirus Biopharmaceuticals, a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that it has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm, a Chinese biotechnology company focused on the development, manufacture, and sale of antibody-based drugs. Livzon was also a principal investor in the $36 million private financing round Epirus closed in April 2014, prior to becoming a public company. Under the terms of the agreement, Epirus and Livzon will work together to develop, manufacture, and commercialize up to five biosimilar products. The first collaboration product is Epirus\' Remicade® biosimilar BOW015 (infliximab), which was recently approved in India. Livzon will conduct any additional development work necessary for the approval of BOW015 in China and Taiwan. Livzon will also serve as the preferred supplier of BOW015 in these territories, following a transfer of Epirus' SCALE™ manufacturing platform. Livzon will be responsible for all commercialization activities in its territories. Epirus' pipeline of biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab), and BOW030 (bevacizumab). Epirus is actively progressing applications for marketing approval for BOW015 in targeted global markets. EPIRUS also plans to initiate an additional Phase 3 trial in Europe in early 2015.
Financial terms:
Latest news:
